Jefferies analyst Roger Song lowered the price target on Aevi (NASDAQ: GNMX) to $0.20 (from $1.25) while maintaining a Hold rating.

Analyst PT Change

Pre-Open Stock Movers 01/03: (OHRP) (CELG) (DBVT) Higher; (AAPL) (LITE) (BMY) Lower (more...)January 3, 2019 9:22 AM JMP Securities Downgrades Aevi (GNMX) to Market PerformJanuary 3, 2019 5:40 AM After-Hours Movers 01/02: (GNMX) (LITE) (AAPL) Lower (more...)January 2, 2019 6:04 PM Aevi Genomic Medicine (GNMX) Reports ASCEND Trial (Parts A & B) of AEVI-001 in Children with ADHD 'Did Not Achieve Statistical Significance on Primary Endpoint'January 2, 2019 4:36 PM Form 8-K Aevi Genomic Medicine, For: Jan 02January 2, 2019 4:33 PM Aevi Genomic Medicine Announces Top-Line Results from Placebo-Controlled ASCEND Trial (Parts A & B) of AEVI-001 in Children with ADHDJanuary 2, 2019 4:30 PM Aevi Genomic Medicine (GNMX) halted, news pendingJanuary 2, 2019 4:27 PM